New Delhi, Feb. 20 -- A recent report from Macquarie Equity Research forecasts significant growth in India's Contract Research, Development, and Manufacturing Organisation (CRDMO) industry, projecting its market value to reach approximately USD 14 billion by 2028, doubling from its current size of USD 7 billion.

The sector is expected to maintain a robust compound annual growth rate (CAGR) of 14 percent, driven by increased pharmaceutical outsourcing and favourable regulatory conditions.

The analysis suggests that regulatory initiatives, particularly the US Biosecure Act, could potentially accelerate this growth trajectory into the high teens, pushing the industry's value to USD 22 billion by 2030.

This growth is particularly significa...